As we all look forward to another prostate cancer awareness month, I find myself reeling with the advances the field has seen in the past year, particularly in the area of hormone sensitive metastatic prostate cancer. We learned that men may live longer if we can radiate the primary tumor if they have low volume […]
San Francisco, CA (UroToday.com) — The End of Prostate Cancer is encouraging all men to learn their risks of prostate cancer during Prostate Cancer Awareness Month (PCAM), which began on September 1. One in nine men will be diagnosed with prostate cancer during their lifetime, making it the most commonly diagnosed cancer among U.S. men, and one of […]
68Ga-RM2 is a bombesin (BBN) analog that targets the gastrin releasing peptide receptors (GRPR) overexpressed in many cancer cells, including prostate cancer (PC). It has been reported to successfully detect primary and recurrent PC. Here, we describe the distribution and range of physiological uptake of 68Ga-RM2 in 95 patients with biochemically recurrent (BCR) PC. Ninety-five […]
Worldwide, renal cell carcinoma (RCC) represents the sixth most frequently diagnosed cancer in men and the 10th in women, accounting for 5% and 3% of all oncological diagnoses, respectively.1 In the United States, a proportion of the increased incidence of RCC can be attributed to obesity as 42% of these diagnoses could be causally linked […]
Basel, Switzerland (UroToday.com) Dr. Kim Chi from Vancouver presented an update on the utilization of PARP inhibitors during the management of castration-resistant prostate cancer (CRPC) session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC).Dr. Chi started by highlighting that August 7, 2019, AstraZeneca announced that Lynparza® (olaparib) met the primary endpoint of significantly increasing the […]
Basel, Switzerland (UroToday.com) Dr. Christopher Sweeny’s talk encompassed systemic therapy for prostate cancer. The spectrum of patients starting androgen deprivation therapy (ADT) for metastatic disease is quite vast. There are patients who present with de novo metastatic disease, and some present after previous radical prostatectomy or radiotherapy. Some of the patients are fit and young and […]
Basel, Switzerland (UroToday.com) Dr. Alberto Briganti presented his wishes for the future treatment of locally advanced prostate cancer. Dr. Briganti mentioned 4 major points where he would like to see progress. The first issue was the intensification of tailored multi-modal approaches. In the past, neoadjuvant androgen deprivation therapy (ADT) prior to surgery had proved to be […]
Basel, Switzerland (UroToday.com) Dr. Michael Hofman discussed PSMA targeted therapies at the management of CRPC session at APCCC 2019, presenting data from both of his groups in Australia. Dr. Hofman notes that theranostics combines targeted therapeutics with a diagnostic companion, for example, a radioactive small molecule targets prostate-specific membrane antigen (PSMA), which is highly overexpressed in […]
This study analyzes the incidence of multiple primary malignant neoplasms (MPN) in patients with testicular cancer (TC), the results are compared with literature findings and assess the rarest subgroup of patients with MPN. Clinical data of 1870 patients with TC treated or followed up in a single center in the period of 5/1970-12/2018 were collected […]
As the most common metastasis site in renal cell carcinoma (RCC) patients, lung and bronchus metastasis (LBM) represents a late stage and a poor prognosis. The purpose of our study is to determine the impact of surgical intervention on prognosis of RCC patients with LBM by means of analysis the data from the Surveillance, Epidemiology […]
